In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target, as …
In a research report issued yesterday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a $34 …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target, following …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target. The analyst noted, “The FDA’s …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price target, following the appointment of John Hodgman, …
In a research report issued today, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following today’s news of the termination of …
In a research note released yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics (SRPT), and a price target of $34.00.
In a research report issued yesterday, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following data release from …
In a research note released today, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics, Inc. (SRPT), and a price target of $52.
